Jennison Associates
ALNY icon

Jennison Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Jennison Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-277,759
Closed -$110M – 567
2025
Q4 		$110M Sell
277,759
-27,104
-9% -$12M 0.07% 124
2025
Q3 		$139M Sell
304,863
-45,207
-13% -$18.4M 0.08% 101
2025
Q2 		$114M Buy
350,070
+40,851
+13% +$11.3M 0.07% 120
2025
Q1 		$83.5M Buy
309,219
+49,306
+19% +$12.7M 0.06% 147
2024
Q4 		$61.2M Buy
+259,913
New +$68.4M 0.04% 200
2016
Q4 		– Sell
-781,656
Closed -$53M – 808
2016
Q3 		$53M Sell
781,656
-193,769
-20% -$13.7M 0.06% 270
2016
Q2 		$54.1M Buy
975,425
+4,972
+0.5% +$313K 0.06% 269
2016
Q1 		$60.9M Sell
970,453
-519,088
-35% -$34.5M 0.06% 251
2015
Q4 		$140M Buy
1,489,541
+7,296
+0.5% +$676K 0.14% 123
2015
Q3 		$119M Buy
1,482,245
+528,598
+55% +$58.7M 0.12% 151
2015
Q2 		$114M Buy
953,647
+7,800
+0.8% +$932K 0.1% 184
2015
Q1 		$98.8M Buy
945,847
+2,876
+0.3% +$291K 0.09% 207
2014
Q4 		$91.5M Sell
942,971
-18,890
-2% -$1.75M 0.09% 222
2014
Q3 		$75.1M Buy
961,861
+1,144
+0.1% +$73.8K 0.07% 248
2014
Q2 		$60.7M Sell
960,717
-91,405
-9% -$5.43M 0.06% 296
2014
Q1 		$70.6M Buy
1,052,122
+33,966
+3% +$2.63M 0.07% 265
2013
Q4 		$65.5M Sell
1,018,156
-113,782
-10% -$6.79M 0.06% 258
2013
Q3 		$72.5M Buy
1,131,938
+146,005
+15% +$7.28M 0.08% 236
2013
Q2 		$30.6M Buy
+985,933
New +$26.2M 0.03% 367

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates's ALNY Position: Q1 2026 in Review

Jennison Associates sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 277,759 shares — an estimated $110M sold.

Jennison Associates first reported a position in ALNY in Q2 2013 and held it in 19 quarters. The position peaked at $140M in Q4 2015. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Jennison Associates reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jennison Associates sold 277,759 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $110M.
  • Jennison Associates first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 19 quarters.
  • Jennison Associates's Alnylam Pharmaceuticals position peaked at $140M in Q4 2015.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.